Home › Trial NCT02935361
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
- Trial IDNCT02935361
- StatusActive Not Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorUniversity of Southern California
- Enrollment33
- Start date2016-11-02
- ConditionsChronic Myelomonocytic Leukemia · Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.